Retatrutide: What the Phase 2 and Phase 3 Trials Have Actually Measured

The short version

Retatrutide is an experimental injectable compound being developed by Eli Lilly. It is not approved — not by the FDA, not anywhere. It is currently in Phase 3 clinical trials (the large, late-stage studies that happen before a drug can be approved). In Phase 2 trials, retatrutide produced the largest weight losses ever documented by a single injectable compound in a controlled clinical setting: up to -24.2% of body weight over 48 weeks at the highest dose studied ^[1]. It also cut liver fat by more than 80% in people with fatty liver disease ^[5], and lowered blood sugar significantly in people with type 2 diabetes ^[2].

How does it do that? It activates three hormone receptors at once — GLP-1, GIP, and glucagon — rather than one or two. GLP-1 and GIP reduce appetite and improve how the body handles glucose (blood sugar). Glucagon adds energy burning. Together, the three-receptor approach produced results that outpaced two-receptor compounds in the trials studied.

The main side effects in trials were nausea, diarrhea, and a modest rise in resting heart rate. Those happened more at higher doses. What the long-term safety picture looks like is still being determined — that is what Phase 3 is for.

What people using it for research report — including the downsides — is on the effects page.

What the trials have established

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide engineered to activate three class-B G-protein-coupled receptors simultaneously: GLP-1R, GIPR, and GCGR. That architecture is the entire game. The GLP-1 arm suppresses appetite and drives glucose-dependent insulin secretion. The GIP arm adds insulinotropic and adipose-tissue effects. The glucagon arm increases energy expenditure and accelerates hepatic lipid metabolism — the mechanism that pushes weight loss beyond what dual-agonist approaches have achieved in head-to-head data.

In the 48-week Phase 2 obesity trial (n=338), retatrutide at 12 mg once weekly produced a mean body-weight change of -24.2% versus -2.1% with placebo ^[1]. At the same dose, 26% of participants lost 30% or more of their body weight — a threshold historically associated only with bariatric surgery.

In the 36-week Phase 2 type 2 diabetes trial (n=281), retatrutide 12 mg reduced HbA1c (glycated hemoglobin — the three-month blood-sugar average) by -2.02% and body weight by -16.94% versus placebo ^[2]. No severe hypoglycemia was reported.

Structural pharmacology work confirmed the triple binding: cryo-EM imaging resolved retatrutide engaging GLP-1R, GIPR, and GCGR simultaneously, with potency ratios of 8.9× at GIPR, 0.3× at GCGR, and 0.4× at GLP-1R relative to the native hormones ^[3].

Phase 3 trials — the TRIUMPH and TRANSCEND programs — are currently underway. The first Phase 3 readout (TRANSCEND-T2D-1, n=537 with type 2 diabetes) showed retatrutide 12 mg reduced HbA1c by a mean 1.94% and body weight by 15.3% from baseline versus -0.81% and -2.6% for placebo, with predominantly mild-to-moderate GI adverse events and no severe hypoglycemia ^[12].

For the complete mechanism picture, see how does retatrutide work. For the trial-by-trial results breakdown, see retatrutide results. The peer-reviewed record is on Retatrutide research.

What is still open

Retatrutide is not approved anywhere. The trials are ongoing. The following remain genuinely uncertain:

Long-term cardiovascular outcomes. A dose-dependent rise in resting heart rate was observed in Phase 2, peaking around week 24 ^[1]. A dedicated cardiovascular outcomes trial (NCT06383390) is underway but has not reported. What this means at scale over years is unknown.

Weight regain after stopping. Analysis of analogous GLP-1-class agents shows substantial weight rebound after discontinuation ^[14]. Whether retatrutide differs is a live research question.

Kidney safety at scale. The TRANSCEND-CKD trial (NCT05929066) is specifically examining renal effects. Data pending.

Long-term lean-mass outcomes. Phase 2 body-composition data confirmed absolute reductions in lean mass alongside fat mass ^[15]. Proportionally less lean was lost than fat, but the absolute figure is clinically significant for older adults.

This is the honest picture — the number that headlines the compound (the 24.2%) is real and large. The unknowns are also real. Both belong in the briefing.

What this site is

Retatrutide Meds is an independent editorial project. It publishes summaries of the peer-reviewed trial literature on retatrutide. It is not a clinic, a pharmacy, or a vendor. The compound is investigational — no retatrutide product is available for prescription or purchase anywhere in the world as of 2026. Gray-market research-labeled material exists but is unregulated, of unverified identity and purity, and outside any clinical oversight.

Every quantitative claim on this site maps to a numbered citation in the Retatrutide references index. Disputed or uncertain claims are labeled as such. No dosing is recommended, because this is not a clinical service.